Ilyang Pharmaceutical Adjusts Influenza Vaccine Supply Contract Amount Downward Due to Delivery Deadline Expiration

Ilyang Pharmaceutical has corrected the contract amount for the 2025-2026 influenza vaccine supply agreement with the Korea Public Procurement Service from 14.29 billion KRW to 13.84 billion KRW.
The adjustment reflects actual delivery performance upon expiration of the delivery deadline. The reduction of approximately 0.46 billion KRW is only 0.3% of the company's market cap, resulting in negligible financial impact.
The counterparty is a reputable government entity, minimizing credit risk, and the amendment is a routine post-contract settlement procedure.
[AI Summary]This amendment is a routine administrative correction with no material impact on shareholder value. The small contract value relative to market cap and high counterparty credibility suggest limited stock price effect.